Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients
详细信息 查看全文
- 作者：Thomas Urupa ; thomas.urup@regionh.dk" class="auth_mail" title="E-mail the corresponding author ; Signe Regner Michaelsena ; Lars Rø ; nn Olsenb ; c ; Anders Tofta ; Ib Jarle Christensend ; Kirsten Grunneta ; Ole Wintherc ; Helle Broholme ; Michael Kosteljanetzf ; Shohreh Issazadeh-Navikasg ; Hans Skovgaard Poulsena ; h ; Ulrik Lassena ; h ; i
- 关键词：Predictive model ; Angiotensin ; Vascular normalization ; Immune activation ; Anti-angiogenic treatment ; Glioblastoma ; Antigen presentation
- 刊名：Molecular Oncology
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：10
- 期：8
- 页码：1160-1168
- 全文大小：1244 K
文摘
- •
Recurrent glioblastoma patients treated with bevacizumab combination therapy were included in the study.
- •
Gene expression profiling of tumor tissue was performed by a customized NanoString platform covering 800 genes.
- •
Expression of angiotensinogen and HLA class II genes were identified as independent predictors for bevacizumab response.
- •
The two genes were included in a predictive model for response.
- •
The predictive model, if validated, can be used to identify patients benefitting from bevacizumab combination therapy.